Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Oxyquinoline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.95 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.95 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.95 |
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.58 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.58 |
| ▸ | MMP13 known ✓ | P45452 | 1/20 | 0.58 |
| ▸ | CCR5 known ✓ | P51681 | 1/20 | 0.58 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.50 |
| ▸ | PARP1 known ✓ | P09874 | 1/20 | 0.50 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.95 |
| ▸ | MMP2 | P08253 | 2/20 | 0.95 |
| ▸ | METAP2 | P50579 | 2/20 | 0.95 |
| ▸ | COMT | P21964 | 1/20 | 0.95 |
| ▸ | METAP1 | P53582 | 1/20 | 0.95 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.78 |
| ▸ | ALOX12 | P18054 | 4/20 | 0.78 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxyquinoline SCHEMBL599825 | 1.00 | TSHR (0.95) | TSHRMMP2METAP2CHRM1COMT | |
| Oxyquinoline SCHEMBL3357862 | 0.98 | TSHR (0.91) | TSHRMMP2METAP2CHRM1COMT | |
| Oxyquinoline SCHEMBL21465316 | 0.98 | TSHR (0.91) | TSHRMMP2METAP2CHRM1COMT | |
| Oxyquinoline SCHEMBL9313294 | 0.98 | TSHR (0.91) | TSHRMMP2METAP2CHRM1COMT | |
| Oxyquinoline SCHEMBL29716519 | 0.98 | TSHR (1.00) | TSHRMMP2METAP2CHRM1COMT | |
| Oxyquinoline SCHEMBL37189 | 0.98 | TSHR (1.00) | TSHRMMP2METAP2CHRM1COMT | |
| Oxyquinoline SCHEMBL29365411 | 0.98 | TSHR (1.00) | TSHRMMP2METAP2CHRM1COMT | |
| Oxyquinoline SCHEMBL253313 | 0.98 | TSHR (1.00) | TSHRMMP2METAP2CHRM1COMT | |
| Oxyquinoline SCHEMBL23522696 | 0.95 | TSHR (0.95) | TSHRMMP2METAP2CHRM1COMT | |
| Oxyquinoline SCHEMBL21465312 | 0.95 | TSHR (0.95) | TSHRMMP2METAP2CHRM1COMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0137132-A2 | Process for the manufacture of 7,16-dioxa-2-aza-10-0-cladinosyl-12-0-desosaminyl-4,5-dihydroxy-6-ethyl-3,5,9,11,13,15-hexamethyl-bicyclo(11.2.1)-hexadeca-1(2)-ene-8-one and novel intermediate used in this process | SOUR PLIVA farmaceutska, Kemijska prehrambena i kozmeticka industrija, n.sol.o. (YU) | 1985-04-17 | — | — | EP | claimed |
| EP-1685129-A4 | OXIME SUBSTITUTED IMIDAZO RING COMPOUNDS | 3M INNOVATIVE PROPERTIES CO (US) | 2008-10-22 | — | — | EP | disclosed |
| CN-1906193-A | Oxime substituted imidazo ring compounds | 3M INNOVATIVE PROPERTIES CO (US) | 2007-01-31 | — | — | CN | disclosed |
| EP-1732566-A2 | 6-AZAINDOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2006-12-20 | — | — | EP | disclosed |
| EP-1685129-A2 | OXIME SUBSTITUTED IMIDAZO RING COMPOUNDS | 3M Innovative Properties Company (US) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005097129-A2 | 6-AZAINDOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005048933-A2 | OXIME SUBSTITUTED IMIDAZO RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-06-02 | — | — | WO | disclosed |
| EP-1115697-B1 | UNSATURATED HYDROXIMIC ACID DERIVATIVES AS PARP INHIBITORS | GENE KUTATO KFT N (HU) | 2004-02-04 | — | — | EP | disclosed |
| EP-0993304-A1 | PHARMACEUTICAL COMPOSITION HAVING ENHANCED ANTITUMOR ACTIVITY AND/OR REDUCED SIDE EFFECTS, CONTAINING AN ANTITUMOR AGENT AND AN HYDROXAMIC ACID DERIVATIVE | N-Gene Research Laboratories Inc. (US) | 2000-04-19 | — | — | EP | disclosed |
| EP-0989862-A1 | PHARMACEUTICAL COMPOSITION WITH ANTIVIRAL ACTIVITY CONTAINING AN HYDROXYMIC ACID DERIVATIVE AND AN ANTIVIRAL AGENT | N-Gene Research Laboratories Inc. (US) | 2000-04-05 | — | — | EP | disclosed |
| WO-1998058676-A1 | PHARMACEUTICAL COMPOSITION HAVING ENHANCED ANTITUMOR ACTIVITY AND/OR REDUCED SIDE EFFECTS, CONTAINING AN ANTITUMOR AGENT AND AN HYDROXAMIC ACID DERIVATIVE | N-GENE RESEARCH LABORATORIES INC. (US) | 1998-12-30 | — | — | WO | disclosed |
| WO-1998058675-A1 | PHARMACEUTICAL COMPOSITION WITH ANTIVIRAL ACTIVITY CONTAINING AN HYDROXYMIC ACID DERIVATIVE AND AN ANTIVIRAL AGENT | N-GENE RESEARCH LABORATORIES INC. (US) | 1998-12-30 | — | — | WO | disclosed |
| WO-1994012480-A1 | 1,3-DIAZACYCLOALKYL OXIME DERIVATIVES | AKZO NOBEL N.V. (NL) | 1994-06-09 | — | — | WO | disclosed |
| EP-0137132-A3 | PROCESS FOR THE MANUFACTURE OF 7,16-DIOXA-2-AZA-10-0-CLADINOSYL-12-0-DESOSAMINYL-4,5-DIHYDROXY-6-ETHYL-3,5,9,11,13,15-HEXAMETHYL-BICYCLO(11.2.1)-HEXADECA-1(2)-ENE-8-ONE AND NOVEL INTERMEDIATE USED IN THIS PROCESS | SOUR PLIVA farmaceutska, Kemijska prehrambena i kozmeticka industrija, n.sol.o. (YU) | 1986-04-02 | — | — | EP | disclosed |
| EP-0137132-A2 | Process for the manufacture of 7,16-dioxa-2-aza-10-0-cladinosyl-12-0-desosaminyl-4,5-dihydroxy-6-ethyl-3,5,9,11,13,15-hexamethyl-bicyclo(11.2.1)-hexadeca-1(2)-ene-8-one and novel intermediate used in this process | SOUR PLIVA farmaceutska, Kemijska prehrambena i kozmeticka industrija, n.sol.o. (YU) | 1985-04-17 | — | — | EP | disclosed |
| EP-0137132-A2 | Process for the manufacture of 7,16-dioxa-2-aza-10-0-cladinosyl-12-0-desosaminyl-4,5-dihydroxy-6-ethyl-3,5,9,11,13,15-hexamethyl-bicyclo(11.2.1)-hexadeca-1(2)-ene-8-one and novel intermediate used in this process | SOUR PLIVA farmaceutska, Kemijska prehrambena i kozmeticka industrija, n.sol.o. (YU) | 1985-04-17 | — | — | EP | disclosed |
| US-4232029-A | 1-Hydroxyimidazole-5-methanamine derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1980-11-04 | — | — | US | disclosed |